Impact of elevated plasma total homocysteine concentration on coronary atherosclerosis in Chinese patients with acute myocardial infarction undergoing primary coronary intervention

International Heart Journal

Volumn 46, Issue 2, 2005, Pages 181-193

  Chua, Sarah ^a   Wu, Chiung Jen ^a   Chang, Hsueh Wen ^b   Hang, Chi Ling ^a   Chen, Chien Jen ^a   Yang, Cheng Hsu ^a   Yip, Hon Kan ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

Author keywords

Acute myocardial infarction; Diffuse coronary atherosclerosis; Hyperhomocysteinemia

Indexed keywords

CREATININE; HOMOCYSTEINE;

ACUTE HEART INFARCTION; ADULT; AMINO ACID BLOOD LEVEL; ANGIOCARDIOGRAPHY; ARTICLE; CHINESE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GENDER; HUMAN; HYPOTHESIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; PRIORITY JOURNAL; RISK FACTOR; SMOKING; ST SEGMENT ELEVATION; AGED; BLOOD; HEART INFARCTION; HYPERCHOLESTEROLEMIA; HYPERTENSION; MIDDLE AGED; RADIOGRAPHY; REGRESSION ANALYSIS; SEX DIFFERENCE; TRANSLUMINAL CORONARY ANGIOPLASTY;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; DIABETES COMPLICATIONS; FEMALE; HOMOCYSTEINE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; REGRESSION ANALYSIS; RISK FACTORS; SEX FACTORS;

EID: 23044439444     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.46.181     Document Type: Article

References (29)

1. Stein JH, McBride PE. Hyperhomocysteinemia and atherosclerotic vascular disease: pathophysiology, screening, and treatment off. Arch Intern Med 1998; 158: 1301-6. (Review)
2. Medina MA, Amores-Sanchez MI. Homocysteine: an emergent cardiovascular risk factor? Eur J Clin Invest 2000; 30: 754-62. (Review)
3. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337: 230-6.
4. Anderson JL, Muhlestein JB, Home BD, et aL Plasma homocysteine predicts mortality independently of traditional risk factors and C-reactive protein in patients with anglographically defined coronary artery disease. Crculation 2000; 102: 1227-32.
5. Danesh J, Lewington S. Plasma homocysteine and coronary heart disease: systematic review of published epidemiological studies. J Cardiovasc Risk 1998; 5: 229-32.
6. Eikelboom JW, Lonne E, Genest J Jr, Hankey G, Yusuf S. Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. Ann Intern Med 1999; 131: 363-75. (Review)
7. Schnyder G, Roffi M, Flammer Y, Pin R, Hess OM. Association of plasma homocysteine with restenosis after percutaneous coronary angioplasty. Eur Heart J 2002; 23: 726-33.
8. Bostom AG, Silbershatz H, Rosenberg IH, et al. Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. Arch Intern Med 1999; 159: 1077-80.
9. Kark JD, Selhub J, Adler B, et al. Nonfasting plasma total homocysteine level and mortality in middle-aged and elderly men and women in Jerusalem. Ann Intern Med 1999; 131; 321-30.
10. Graham IM, Daly LE, Refsurn RM, et aL Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA 1997; 277: 1775-81.
11. Ueland PM, Refsum H. Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease and drug therapy. J Lab Gin Med 1989; 114:473-501. (Review)
12. Jacobsen DW. Homocysteine and vitamins in cardiovascular disease. Clin Chem 1998; 44: 1833-43. (Review)
13. Nallamothu BY, Fendrick AM, Omenn GS. Homocyst(e)ine and coronary heart disease: pharmacoeconomic support for interventions to lower hyperhomocyst(e)inemia. Pharmacoeconomics 2002; 20: 429-42. (Review)
14. Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH. Total homocysteine in plasma or serum: methods and clinical applications. Clin Chem 1993; 39: 1763-79. (Review)
15. Hermiller JB, Cusma JT, Spero LA, Fortin DF, Harding MB, Bashore TM. Quantitative and qualitative coronary angiographic analysis: review of methods, utility, and limitations. Cathet Cardiovasc Diagn 1992; 25: 110-31. (Review)
16. Garcia-Tevijano ER, Berasain C, Rodriguez JA, et al. Hyperhoinocysteinemia in liver cirrhosis: mechanisms and role in vascular and hepatic fibrosis. Hypertension 2001; 38: 1217-21.
17. Kaye JM, Stanton KG, McCann VJ, et al. Homocysteine, folate, methylene teftahydrofolate reductase genotype and vascular morbidity in diabetic subjects. Clinical Science 2002; 102: 631-7.
18. Bostom AG, Culleton BF. Hyperhomocysteinemia in chronic renal disease. J Am Soc Nephrol 1999; 10: 891-900. (Review)
19. Stein JH, Bushara M, Bushara Y, McBride PE, Jorenby DE, Fiore MC. Smoking cessation, but not smoking reduction, reduces plasma homocysteine levels. Clin Cardiol 2002; 25: 23-6.
20. Hoogeveen EK, Kostense PJ, Jakobs C, et al. Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes: 5-year follow-up of the Hoorn Study. Circulation 2000; 101: 1506-11.
21. Knekt P, Reunanen A, Alfthan G, et al. Hyperhornocystinemia: a risk factor or a consequence of coronary heart disease. Arch Intern Med 2001; 161: 1589-94.
22. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-9. (Review)
23. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998; 338: 1042-50. (Review)
24. Chai AU, Abrams J. Hornocysteine: a new cardiac risk factor? Clin Cardiol 2001; 24: 80-4. (Review)
25. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049-57.
26. Refsum H, Ueland PM, Nygard O, Vollset SE. Homocysteine and cardiovascular disease. Annu Rev Med 1998; 49: 31-62. (Review)
27. Fallon UB, Ben-Shlomo Y, Elwood P, Ubbink JB, Smith GD. Homocystrine and coronary heart disease in the Caerphilly cohort: a 10 year follow up. Heart 2001; 85: 153-8.
28. Cleophas TJ, Hornstra N, van Hoogstraten B, van der Meulen J. Homocysteine, a risk factor for coronary artery disease or not? A meta-analysis. Am J Cardiol 2000; 86: 1005-9.
29. Falk E, Zhou J, Moller J. Homocysteine and atherothrombosis. Lipids; 2001; 36: S3-11. (Review)